Search
Research
A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)V114 (15-valent pneumococcal conjugate vaccine [PCV]) contains all serotypes in 13-valent PCV (PCV13) and additional serotypes 22F and 33F. This study evaluated safety and immunogenicity of V114 compared with PCV13 in healthy infants, and concomitant administration with DTPa-HBV-IPV/Hib and rotavirus RV1 vaccines.
Research
The non-specific effects of maternal immunization on birth outcomes: The evidence, mechanisms, and the implicationsPreterm birth (PTB) and stillbirth remain two of the most important causes of death, morbidity, and disability in childhood. Despite efforts to reduce PTB and stillbirth worldwide, rates of these adverse outcomes remain persistently elevated, independent of income setting. There is an urgent need for more effective interventions to reduce associated neonatal and early childhood morbidity and mortality.
Research
Clinician perceptions of research priorities for the management of noncritically ill patients admitted to hospital with SARS-CoV-2 infectionThe changing phenotype of coronarvirus disease 2019 (COVID-19) may quickly render guideline-recommended interventions obsolete. We developed a 40-question clinician survey in consultation with the Australasian COVID-19 Trial site investigators. The survey was designed to assess clinician perceptions of the current treatment strategies and future research priorities in the management of non-critically ill patients admitted to hospital with SARS-CoV-2 infection.
Research
Incremental effectiveness of 23-valent pneumococcal polysaccharide vaccine against pneumonia hospitalisation among Australian Indigenous children: A record linkage studyThe impact of pneumococcal conjugate vaccines (PCVs) on pneumonia in children is well-documented but data on 23-valent pneumococcal polysaccharide vaccine (PPV23) are lacking. Between 2001 and 2011, Indigenous children in Western Australia (WA) were recommended to receive PPV23 at 18-24 months of age following 3 doses of 7-valent PCV. We evaluated the incremental effectiveness of PPV23 against pneumonia hospitalisation.
Research
Opportunities and challenges of the pulmonary route for vaccinationThe respiratory tract is an attractive target for the delivery of vaccine antigens.
Research
Preterm infants have deficient monocyte and lymphocyte cytokine responses to group B streptococcusGroup B streptococcus (GBS) is an important cause of early- and late-onset sepsis in the newborn. Preterm infants have markedly increased susceptibility...
News & Events
Rheumatic heart disease remains a major killer in Oceania regionA new study shows that people living in the Oceania region, including Australia, have the highest risk in the world of dying from rheumatic heart disease.
News & Events
Extra whooping cough shot to protect your bubToddlers will now get an additional whooping cough vaccine to protect them against the potentially deadly disease.
News & Events
Taking on a common respiratory infection in kidsMapping when Respiratory Syncytal Virus (RSV) reaches its seasonal peak will assist how future vaccination programs are carried out.
News & Events
Video: Flu vaccine Q&AIt's that time of year again... Flu vaccine time! Watch Dr Chris Blyth answer commonly asked questions in the video below.